Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Selected publications (Pre-HERC)

Doble B. Budget impact and cost-effectiveness: can we afford precision medicine in oncology? Scand. J. Clin. Lab. Invest. Suppl. 2016;245: S6-S11.

Doble B, John, T, Thomas, D, Fellowes, A, Fox, S, Lorgelly, P Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer [Epub 2016 Jun 2]

Doble B, Schofield DJ, Roscioli T, Mattick JS. The promise of personalised medicine. The Lancet 2016;387(10017):433-434.

Doble B, Lorgelly P. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms. Quality of Life Research 2016;25(4):891-911. [Epub 2015 Sept 21]

Doble B, Lorgelly P. Clinical players and health care payers: aligning perspectives on the cost-effectiveness of next-generation sequencing in oncology. Personalized Medicine 2015;12(1):9-12.

Doble B, Tan M, Harris A, Lorgelly P. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist. Expert Review of Molecular Diagnostics 2015;15(2):234-254. [Epub 2014 Aug 21]

Doble B, Harris A, Thomas DM, Fox S, Lorgelly P. Multiomics medicine in oncology: assessing effectiveness, cost–effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics 2013;14(12):1405-1417.

Doble B, Blackhouse G, Goeree R, Xie F. Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared to standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: a Canadian perspective. Journal of Thoracic and Cardiovascular Surgery 2013;146(1):52-60.e3. [Epub 2012 Jul 11]

Brett Doble

BSc, MSc, PhD

Senior Researcher

Brett is a health economist, with international experience in academic research, consulting and the pharmaceutical industry. He received his PhD in Health Economics from the Centre for Health Economics, Monash University where he was the recipient of the Donald Cochrane Research Scholarship. He received his BSc in Biochemistry and MSc in Clinical Epidemiology and Biostatistics from McMaster University where he was a Canadian Institutes of Health Research Strategic Training Fellow for Drug Safety and Effectiveness.

Prior to joining HERC, Brett was a Research Associate in Health Economics at the Cambridge Centre for Health Services Research, University of Cambridge and still holds a Visiting Researcher position in the Department of Public Health and Primary Care. Brett also has an affiliation with the Garvan Institute of Medical Research in Australia where he has consulted on projects related to the economic impacts of implementing whole genome sequencing into routine clinical practice.

Currently, Brett is involved in two large clinical studies, one assessing the cost-effectiveness of different approaches to bariatric surgery for the treatment of severe obesity and another assessing the impact of bleeding events on the cost-effectiveness of different combinations of dual antiplatelet therapy after coronary interventions. His main research interests are, however, related to the economics of genomic medicine, with a particular interest in its applications in oncology and monogenic diseases. He has completed a number of economic evaluations of health technologies using within-trial analyses and decision analytic modelling and has an interest in further developing economic methods for assessing diagnostic tests within the genomics context. Brett also has an interest in health outcomes research, specifically the use of ‘mapping’ to generate health state utility values.